Sign up

Caligan Partners LP

$2.1B assets · 25 holdings · Q2 2026 · Filed 14 AUG 2026

About Caligan Partners LP’s 13F portfolio

Caligan Partners LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Caligan Partners LP reported $2.1B across 25 US-listed positions (). Its largest position is LIQUIDIA CORPORATION (LQDA) at 31% of the reported book, and its ten biggest holdings make up 83% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$2.1B
Assets (13F)
#1,450
of 8,839 by size
25
Holdings
83%
Top-10 weight
15
Buys
7
Sells
Top holdings · Q2 2026
25 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: LQDA
LIQUIDIA CORPORATION
—
—
31%
8.1M$647.3M
2
NASDAQ: RVMD
REVOLUTION MEDICINES INC
—
—
18%
2.0M$367.4M
3
NASDAQ: ABVX
ABIVAX SA
—
—
10%
1.6M$207.6M
4
NASDAQ: PCVX
VAXCYTE INC
—
—
6.1%
2.2M$127.2M
5
NASDAQ: EXEL
EXELIXIS INC
—
—
4.1%
1.6M$84.5M
6
NASDAQ: TNGX
TANGO THERAPEUTICS INC
—
—
3.8%
2.5M$78.2M
7
NASDAQ: AVTX
AVALO THERAPEUTICS INC
—
—
2.8%
3.2M$58.5M
8
NASDAQ: XENE
XENON PHARMACEUTICALS INC
—
—
2.6%
890K$53.7M
9
NASDAQ: ADMA
ADMA BIOLOGICS INC
—
—
2.3%
5.7M$47.9M
10
NASDAQ: LBRX
LB PHARMACEUTICALS INC
—
—
2.3%
1.4M$46.7M
11
NASDAQ: IMCR
IMMUNOCORE HLDGS PLC
—
—
2.1%
1.4M$43.9M
12
NASDAQ: VRDN
VIRIDIAN THERAPEUTICS INC
—
—
1.9%
2.2M$40.3M
13
NASDAQ: VOR
VOR BIOPHARMA INC
—
—
1.7%
1.9M$35.4M
14
NASDAQ: SABS
SAB BIOTHERAPEUTICS INC
—
—
1.5%
8.0M$31.1M
15
NASDAQ: IVA
INVENTIVA SA
—
—
1.5%
8.2M$30.9M
16
NASDAQ: AURA
AURA BIOSCIENCES INC
—
—
1.5%
4.3M$30.5M
17
NASDAQ: TYRA
TYRA BIOSCIENCES INC
—
—
1.2%
807K$25.8M
18
NASDAQ: IRD
OPUS GENETICS INC
—
—
1.2%
6.1M$25.0M
19
NASDAQ: ANIK
ANIKA THERAPEUTICS INC
—
—
1.0%
1.4M$21.0M
20
NASDAQ: SGMT
SAGIMET BIOSCIENCES INC
—
—
0.9%
2.5M$19.3M
21
NASDAQ: ARTV
ARTIVA BIOTHERAPEUTICS INC
—
—
0.8%
1.7M$16.8M
22
NASDAQ: SNSE
FAETH THERAPEUTICS INC
—
—
0.8%
629K$15.7M
23
NASDAQ: MBX
MBX BIOSCIENCES INC
—
—
0.5%
200K$11.0M
24
NASDAQ: VRCA
VERRICA PHARMACEUTICALS INC
—
—
0.3%
924K$5.7M
25
NASDAQ: CLRB
CELLECTAR BIOSCIENCES INC
—
—
0.1%
470K$1.3M

Showing the 25 largest positions reported in this 13F.

Sector allocation
  • Healthcare100%
Recent activity · vs 2026-03-31
Bought15
  • AddedRVMDREVOLUTION MEDICINES INC+18.7%$367.4M
  • AddedABVXABIVAX SA+6.6%$207.6M
  • AddedPCVXVAXCYTE INC+6.2%$127.2M
  • AddedTNGXTANGO THERAPEUTICS INC+3.8%$78.2M
  • AddedAVTXAVALO THERAPEUTICS INC+93.5%$58.5M
  • AddedADMAADMA BIOLOGICS INC+20.4%$47.9M
  • NewIMCRIMMUNOCORE HLDGS PLC—$43.9M
  • NewVRDNVIRIDIAN THERAPEUTICS INC—$40.3M
  • AddedIVAINVENTIVA SA+64.1%$30.9M
  • AddedAURAAURA BIOSCIENCES INC+1770%$30.5M
Sold7
  • ReducedXENEXENON PHARMACEUTICALS INC−36.1%$53.7M
  • ReducedTYRATYRA BIOSCIENCES INC−36.8%$25.8M
  • ReducedMBXMBX BIOSCIENCES INC−76.4%$11.0M
  • SoldMLYSMINERALYS THERAPEUTICS INC−100%—
  • SoldSYRESPYRE THERAPEUTICS INC−100%—
  • SoldXLOXILIO THERAPEUTICS INC−100%—
  • SoldMAZEMAZE THERAPEUTICS INC−100%—
5%+ Beneficial Ownership Stakes · 1 activist (13D) · 1 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
ANIK
Anika Therapeutics, Inc.
13D9.9%1.4MFiled 27 JAN 2026
2
SABS
SAB Biotherapeutics, Inc.
13G8.8%8.0MFiled 14 AUG 2026

Showing all 2 disclosed stakes.

Reading Caligan Partners LP’s 13F portfolio

Caligan Partners LP’s $2.1B 13F book is spread across 25 reported positions and is highly concentrated — its ten largest positions alone are 83% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are LQDA, RVMD, ABVX, PCVX and EXEL, led by LIQUIDIA CORPORATION (LQDA) at 31% of the portfolio. The heaviest sector exposure is Healthcare (100%).

What Caligan Partners LP changed last quarter

Between 2026-03-31 and Q2 2026, Caligan Partners LP was a net buyer: it opened 5 new positions and added to 10 more, while trimming 3 and closing 4 outright. Against a 25-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was REVOLUTION MEDICINES INC (RVMD), and its biggest reduction was XENON PHARMACEUTICALS INC (XENE).

What a 13F does and doesn’t reveal

A 13F captures only Caligan Partners LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Caligan Partners LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Caligan Partners LP's profile on this page is built directly from those filings.

How current is the 13F data on Caligan Partners LP's page?

It reflects Caligan Partners LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Caligan Partners LP files its next quarterly report, this page refreshes automatically.

Can I see Caligan Partners LP's complete list of holdings?

This page highlights Caligan Partners LP's largest positions rather than all 25 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Caligan Partners LP's filings.

Does a 13F show everything Caligan Partners LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Caligan Partners LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Caligan Partners LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.